MedTrace Logo

Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies

NCT06646263 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-10-17

No results posted yet for this study

Summary

This project introduces a novel methodology for the in-depth immunogenetic characterization of the TR gene repertoire in solid tumors, holding the promise to offer unprecedented insights into the TR anti-tumor specificity and the prognostic/predictive value of TR gene repertoire signatures.

Conditions

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    collaborator OTHER

  • Institute of Applied Biosciences

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2027-04-30
Completion
2028-04-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06646263 on ClinicalTrials.gov